Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -158.9%. (2003–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $705406 | $59M | $111M | $192M | $274M | $499M | $504M | $665M | $706M | $81M | $51M |
| Enterprise Value | $9M | $67M | $120M | $201M | $277M | $494M | $504M | $666M | $697M | $88M | $71M |
| P/E Ratio → | -0.09 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.02 | 1.91 | 3.30 | 5.76 | 7.58 | 16.64 | 21.83 | 21.06 | 23.66 | 2.58 | 1.60 |
| P/B Ratio | 1.92 | 20.15 | 22.28 | 15.14 | 12.56 | 19.63 | 19.47 | 23.22 | 22.60 | 3.65 | 3.46 |
| P/FCF | — | — | — | — | — | — | — | — | 622.85 | 33.81 | — |
| P/OCF | — | — | 589.30 | — | — | 330.79 | 240.53 | 298.45 | 243.89 | 19.61 | 158.22 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.18 | 3.57 | 6.02 | 7.67 | 16.49 | 21.85 | 21.08 | 23.35 | 2.79 | 2.23 |
| EV / EBITDA | — | — | — | — | 266.83 | — | — | 367.64 | 341.44 | 22.34 | 25.59 |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | 614.84 | 36.52 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 58.3% | 58.3% | 56.9% | 55.3% | 60.2% | 66.2% | 61.2% | 64.2% | 57.3% | 57.1% | 60.2% |
| Operating Margin | -19.0% | -19.0% | -27.6% | -25.8% | -12.9% | -14.7% | -17.7% | -9.5% | -11.2% | -7.7% | -11.3% |
| Net Profit Margin | -20.4% | -20.4% | -30.1% | -32.5% | -15.3% | -9.0% | -19.1% | -12.0% | -13.5% | -68.4% | -10.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -158.9% | -158.9% | -114.2% | -62.7% | -23.5% | -10.5% | -16.2% | -12.7% | -15.1% | -116.4% | -21.7% |
| ROA | -18.8% | -18.8% | -25.8% | -23.0% | -11.2% | -5.8% | -9.4% | -8.0% | -9.4% | -52.6% | -7.1% |
| ROIC | -34.4% | -34.4% | -38.9% | -27.8% | -15.3% | -14.0% | -11.0% | -8.8% | -9.9% | -5.7% | -7.9% |
| ROCE | -46.1% | -46.1% | -36.0% | -25.1% | -12.8% | -14.3% | -14.1% | -8.7% | -9.6% | -7.1% | -8.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 5.59 | 5.59 | 3.31 | 1.23 | 0.39 | 0.32 | 0.42 | 0.30 | 0.24 | 0.48 | 1.62 |
| Debt / EBITDA | — | — | — | — | 8.12 | — | — | 4.79 | 3.62 | 2.70 | 8.61 |
| Net Debt / Equity | — | 2.87 | 1.85 | 0.70 | 0.14 | -0.18 | 0.01 | 0.02 | -0.29 | 0.29 | 1.35 |
| Net Debt / EBITDA | — | — | — | — | 2.89 | — | — | 0.30 | -4.45 | 1.66 | 7.19 |
| Debt / FCF | — | — | — | — | — | — | — | — | -8.02 | 2.72 | — |
| Interest Coverage | -2.98 | -2.98 | -3.87 | -5.66 | -4.92 | -7.51 | -18.61 | -5.84 | -2.94 | -0.56 | -0.73 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.58 | 0.58 | 1.13 | 1.28 | 1.30 | 1.56 | 1.32 | 1.35 | 2.69 | 1.40 | 1.75 |
| Quick Ratio | 0.48 | 0.48 | 0.98 | 1.06 | 0.89 | 1.29 | 1.14 | 1.18 | 2.37 | 1.01 | 1.29 |
| Cash Ratio | 0.30 | 0.30 | 0.50 | 0.56 | 0.40 | 0.98 | 0.56 | 0.47 | 1.91 | 0.53 | 0.64 |
| Asset Turnover | — | 1.01 | 0.93 | 0.79 | 0.69 | 0.64 | 0.49 | 0.67 | 0.63 | 0.81 | 0.74 |
| Inventory Turnover | 4.55 | 4.55 | 6.45 | 5.57 | 2.59 | 2.90 | 2.60 | 3.74 | 4.56 | 4.49 | 4.49 |
| Days Sales Outstanding | — | 49.00 | 57.13 | 48.58 | 45.13 | 41.80 | 46.54 | 50.68 | 41.48 | 36.45 | 38.96 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | 0.2% | 3.0% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $47M | $38M | $35M | $35M | $34M | $34M | $32M | $27M | $7M | $2M |
Liquidity and solvency constraints
According to recent market data, SSKN trades at a price-to-sales multiple of 0.02, a valuation level that suggests investors are heavily discounting the company's future growth prospects and questioning the long-term viability of the current business model given the persistent lack of positive earnings.
The extremely low P/S ratio indicates that the market is pricing the company as a distressed asset rather than a growth-oriented medical device firm. This valuation implies that investors are skeptical about the company's ability to scale the TheraClear X platform and achieve the operating leverage necessary to justify a higher multiple.
Based on reported figures, SSKN's ROIC has struggled to remain positive, fluctuating between -19.3% and 0.3% over the last ten quarters, which highlights a fundamental inability to generate adequate returns on the capital deployed into its laser placement program.
The persistent negative ROIC suggests that the cost of maintaining the installed base of lasers consistently outweighs the incremental revenue generated by those units. This trend warrants further investigation into whether the current partnership model can ever achieve the necessary utilization rates to become self-funding.
As reported in financial statements, the company's cash conversion cycle has remained volatile, reaching 40 days in 2025Q4, which reflects ongoing challenges in managing inventory and receivables effectively within the complex, service-heavy structure of the dermatology partnership program.
The variability in the cash conversion cycle suggests that the company faces significant friction in its operational workflow, likely exacerbated by the need to manage a geographically dispersed fleet of equipment. Investors should monitor whether these inefficiencies are structural or if they can be mitigated through improved logistics and service management.
Based on the latest balance sheet data, SSKN's debt-to-equity ratio has surged to 5.59 in 2025Q4, a significant deterioration that indicates the company's reliance on debt has intensified as its equity base has been eroded by persistent operating losses over the past two years.
This high leverage ratio, combined with an interest coverage ratio of 0.08, suggests that the company is operating with minimal financial cushion and faces substantial refinancing risk. The current debt load appears to be a major headwind that limits management's ability to invest in growth initiatives without further dilutive capital raises.
Analysts frequently misapply the P/E ratio to SSKN, a metric that is fundamentally misleading for a company currently experiencing negative net margins and significant operational volatility, thereby obscuring the true cash-generating potential of its recurring revenue model.
Because the company is in a capital-intensive growth phase with heavy depreciation charges, the P/E ratio fails to capture the underlying economics of the partnership program. A more appropriate metric would be an adjusted EBITDA or a cash-on-cash return analysis of the installed laser base, which would better reflect the company's operational performance.
Includes 30+ ratios · 23 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SSKN stock.
STRATA Skin Sciences, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
STRATA Skin Sciences, Inc.'s return on equity (ROE) is -158.9%. The historical average is -83.5%.
Based on historical data, STRATA Skin Sciences, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
STRATA Skin Sciences, Inc. has 58.3% gross margin and -19.0% operating margin.